Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-01-13-Speech-2-385"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20090113.29.2-385"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Madam President, I welcome the Commission’s statement tonight and look forward to reading in more detail exactly what is in this package.
Some years ago here we had the pharmaceutical review. That included veterinary medicines, as well as human pharmaceuticals. I am just wondering why the two have been divorced at this stage in the proceedings. The Commission will be aware of my interest through the legislation on maximum residues, which feed into the food chain through veterinary pharmaceuticals. I have been critical of serious shortcomings in the Veterinary Medicines Directive now for some time.
Could the Commissioner just comment on drug interaction and multi-drug therapy and drug-resistance issues in relation to this discussion here tonight? I, like others, feel there should be far more patient information now. Patients should not have to ‘compete’ – if that is the word – with what is on the internet, where there is sometimes a lot of misinformation. They should get properly reviewed scientific information at first hand with their medicines.
Finally, I also have concerns with the role of drug companies in influencing doctors’ prescription habits. Could the Commissioner comment, please?"@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples